Overview

Neoadjuvant HS-10296 (Almonertinib) Therapy for Resectable Stage III EGFR Mutation-Positive Lung Adenocarcinoma

Status:
Not yet recruiting
Trial end date:
2027-12-31
Target enrollment:
Participant gender:
Summary
This is a phase II, single-arm, open-label study to evaluate the efficacy and safety of the third generation tyrosine kinase inhibitors (TKIs) Almonertinib (HS-10296) as neoadjuvant and adjuvant therapy for resectable stage III EGFR mutation-positive lung adenocarcinoma.
Phase:
Phase 2
Details
Lead Sponsor:
Shanghai Pulmonary Hospital, Shanghai, China